Comparison of Central and Peripheral Nervous System Lesions Caused by High-Dose Short-Term and Low-Dose Subchronic Acrylamide Treatment in Rats

Abstract

The effects of high-dose subacute acrylamide treatment of up to 50 mg/kg/day for 4 or 10 d were compared to those of subchronic exposure, up to 12 mg/kg/day for 90 d. In the subacute study, Purkinje cells, long ascending tracts of the spinal cord, optic tract terminal or preterminal regions in superior colliculus, sensory ganglion cells, and distal large-caliber peripheral axons were severely affected. Purkinje cells and fasciculus gracilis changes were the earliest lesions. In the subchronic study, the dominant lesion was confined to the distal peripheral axon, with only minor changes occurring in spinal cord and medulla. Paranodal swellings with the characteristic appearance of neurofilament aggregations were not seen. This morphological study suggests a significant difference between high- and low-dose acrylamide-induced lesions. If there is a reduced tendency for long-term low-dose acrylamide exposure to produce CNS lesions, the risk of irreversible nervous system damage would be less than that predicted from subacute studies.

References

1. Altia M and Linnoila I (1978). Distal axonopathy induced by carbon disulfide. J. Neuropathol. Exp. Neurol. 37: 621.

2. Cavanagh JB (1954). The toxic effects of tri-ortho cresyl phosphate. J. Neurol. Neurosurg. Psychiat. 17:163–172.

3. Cavanagh JB (1973). Peripheral neuropathy caused by chemical agents. CRC Crit. Rev. Toxicol. 2:365–417.

4. Cavanagh JB (1979). The dying back process. A common denominator in many naturally occurring and toxic neuropathies. Arch. Pathol. Lab. Med. 103:659–664.

5. Cavanagh JB (1982). The pathokinetics of acrylamide intoxication: A reassessment of the problem. Neuropathol. Appl. Neurobiol 8:315–336.

6. Cavanagh JB and Nolan DD (1982). Selective loss of Purkinje cells from the rat cerebellum caused by acrylamide and the responses of B-glucuronidase and B-galactosidase. Acta Neuropathol. 58:210–214.

7. Fullerton P and Barnes J (1966). Peripheral neuropathy in rats produced by acrylamide. Brit. J. Ind. Med. 23:210–221.

8. Jones HB and Cavanagh JB (1983). Distortions of the nodes of Ranvier from axonal distension by filamentous masses in hexacarbon intoxication. J. Neurocytol. 12:439–458.

9. Jones HB and Cavanagh JB (1984). The evolution of intracellular responses to acrylamide in rat spinal ganglion neurons. Neuropathol. Appl. Neurobiol. 10:101–121.

10.

10. Kuperman AS (1958). Effects of acrylamide on the central nervous system of the cat. J. Pharmacol. Exp. Therap. 123:180–192.

11.

11. McCollister DD , Oyen F , and Rowe VK (1964). Toxicology of acrylamide. Toxicol. Appl. Pharmacol. 6:172–181.

12.

12. Merigan WH , Barkdoll E , and Maurissen JPJ (1982). Acrylamide-induced visual impairment in primates. Toxicol. Appl. Pharmacol. 62:342–345.

13.

13. Prineas J (1969). The pathogenesis of dying back polyneuropathies. II. An ultrastructural study of experimental acrylamide intoxication in the cat. J. Neuropathol. Exp. Neurol. 28:598–621.

14.

14. Schaumburg HH , Wisniewski HM , and Spencer PS (1974). Ultrastructural studies of the dying-back process. 1. Peripheral nerve terminal and axon degeneration in systemic acrylamide intoxication. J. Neuropathol. Exp. Neurol. 33:260–284.

15.

15. Spencer PS and Schaumburg HH (1974). A review of acrylamide neurotoxicity. Part I. Properties, uses, and human exposure. Can. J. Neurol. Sci. 1:143–150.

16.

16. Spencer PS and Schaumburg HH (1974). A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can. J. Neurol. Sci. 1:152–169.

17.

17. Spencer PS and Schaumburg HH (1975). Experimental neuropathy produced by 2,5-hexanedione—A major metabolite of the neurotoxic industrial solvent methyl. N-butyl ketone. J. Neurol. Neurosurg. Psychiat. 38:771–775.

18.

18. Spencer PS and Schaumburg HH (1977). Central-peripheral distal axonopathy—The pathology of dying back polyneuropathies. In: Progress in Neuropathology, Vol. 3, H Zimmerman (ed). Grune & Stratton, New York, N.Y., pp. 253–295.

19.

19. Spencer PS and Schaumburg HH (1977). Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J. Neuropathol. Exp. Neurol. 36:276–299.

20.

20. Spencer PS , Schaumburg HH , Ralaeigh RL , and Terhaar CJ (1975). Nervous system degeneration produced by the industrial solvent methyl N-butyl ketone. Arch. Neurol. 32:219–222.

21.

21. Sterman AB (1982). Acrylamide induces early morphologic reorganization of the neuronal cell body. Neurology 32:1023–1026.

22.

22. Sterman AB and Sheppard RC (1983). A correlative neurobehavioral-morphological model of acrylamide neuropathy. Neurobehav. Toxicol. Teratol. 5:151–159.